Olmesartan Duo Tablet 20/5 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Donggu Biopharmaceutical Co., Ltd.
MFDS item code 202003967 · Approved 2020.05.28
This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Hypertension, dyslipidemia, inhibition of atherosclerotic progression and cardiovascular disease risk
This medication is used for patients who need to take olmesartan medoxomil and rosuvastatin together. Olmesartan medoxomil is primarily effective for the treatment of essential hypertension. Rosuvastatin helps control hypercholesterolemia and dyslipidemia, serving as an adjunct therapy when dietary changes or exercise are insufficient. It is also effective for the treatment of homozygous and heterozygous familial hypercholesterolemia and for delaying the progression of atherosclerosis. In patients at high risk for cardiovascular diseases, it also helps reduce the risks of stroke, myocardial infarction, and arterial revascularization. Therefore, this medication is used to simultaneously improve hypertension and dyslipidemia and to reduce the risk of cardiovascular diseases.
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Children under 18 years of age: Safety and efficacy have not been established.
This medication can cause severe harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used by women who are allergic to any of the components, pregnant or breastfeeding women, patients with severely impaired kidney or liver function, and patients with certain muscle disorders. In particular, women of childbearing potential should ensure adequate contraception to avoid pregnancy and should only take this medication after fully understanding the risks to the fetus, even if the likelihood of pregnancy is low. Caution should be exercised when administering this medication to patients with reduced kidney function or blood volume, as it may lead to hypotension or impaired kidney function. Due to the risk of hyperkalemia, serum potassium levels should be regularly monitored and managed. This medication may affect liver function, so caution is necessary for patients with a history of liver disease or abnormal liver function test results, and repeated liver function tests may be needed as necessary. If symptoms such as muscle pain or weakness occur, contact a healthcare professional immediately to check for possible muscle damage through blood tests. Extra caution is advised for patients with a history of excessive alcohol consumption or liver disease. Dizziness or drowsiness may occur during treatment, so it is advisable to avoid driving or operating hazardous machinery. Moreover, this medication may interact with certain other medications; therefore, if other medications are being taken, consult a physician or pharmacist. It is safest for pregnant and breastfeeding women not to take this medication; if breastfeeding, either cessation of breastfeeding or stopping the medication should be considered. The safety and efficacy of this medication for children and adolescents under 18 years have not been established, so use is not recommended. Elderly patients may have increased concentrations of this medication in the body, so dose adjustment and careful monitoring are necessary. In case of overdose, symptoms such as hypotension and palpitations may appear, and immediate medical treatment should be sought. This medication should be stored out of reach of children and not transferred to another container.
ALT elevation, AST elevation, increased serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute kidney failure, hair loss, itching, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), headache, palpitations, increased blood pressure, low back pain, increased serum creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect against air and moisture and should be kept at room temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the effectiveness of the medication for a longer period.
White or pale yellow round film-coated tablets
30 tablets/box [10 tablets/Alu-Alu x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Donggu Biopharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.